The effects of combined calcium and vitamin D supplementation on bone mineral density and fracture risk in postmenopausal women with osteoporosis: a systematic review and meta-analysis of randomized controlled trials

钙和维生素D联合补充剂对绝经后骨质疏松症女性骨密度和骨折风险的影响:一项随机对照试验的系统评价和荟萃分析

阅读:1

Abstract

PURPOSE: This systematic review and meta-analysis assesses the efficacy of combined calcium and vitamin D supplementation on bone mineral density (BMD) and fracture risk among postmenopausal women with osteoporosis. METHODS: We conducted a comprehensive search across multiple medical databases including PubMed, Embase, Cochrane Library, and Web of Science, collecting randomized controlled trials (RCTs) published from database inception to present. Data extraction and analysis were performed to calculate standardized mean differences (SMDs) or risk ratios (RRs) with 95% confidence intervals (CIs), which were then presented in forest plots. RESULTS: Eleven RCTs with 43,869 participants were included. Combined supplementation modestly improved BMD at the pelvis (SMD = 0.20, 95% CI: 0.05–0.35, p = 0.01) without significant changes in BMD at the lumbar spine, femoral neck, or total hip. The overall fracture risk was not significantly reduced (RR = 0.98, 95% CI: 0.89–1.07, p = 0.68). Subgroup analyses revealed improvements in serum 25‑hydroxyvitamin D levels (25OHD), especially in participants with baseline deficiencies (Z = 10.48, p < 0.001). No dose-response effect was noted for supplementation duration. Fracture outcomes from three large trials (> 42 000 participants) yielded a neutral effect on any clinical fracture (pooled RR = 0.95; 95% CI 0.85–1.07; Z = 1.08, P = 0.28; I² = 0%). Sensitivity analyses affirmed the findings’ stability, with no evident publication bias. CONCLUSION: Combined calcium and vitamin D supplementation may improve pelvic BMD and correct serum 25OHD deficiencies in postmenopausal women with osteoporosis, but does not reduce clinical fracture risk in postmenopausal women with osteoporosis. Larger, highdose RCTs with rigorous adherence monitoring and adjudicated fracture endpoints are warranted. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-025-09089-7.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。